Korean Circ J.  1990 Mar;20(1):128-134. 10.4070/kcj.1990.20.1.128.

Effect of Pravastatin on Serum Lipids of Patient with Primary Hyperlipidemia

• Yoo WS
• Koh WS
• Cho BY
• Choi SK

• KMID: 2229394
• DOI: http://doi.org/10.4070/kcj.1990.20.1.128

Abstract

A new hypolipidemic drug, pravastatin, hydroxymethylglutaryl coenzyme A reductase inhibitor was administered to 33 patients with primary hyperlipidemia, 10mg daily for 8 weeks and sequential changes of lipid profile were analysed as follows. 1) Mean value at baseline period of total cholesterol, triglyceride, high and low density lipoprotein cholesterol were 260, 220, 51 and 163mg/dl respectively. 2) Total cholesterol showed 21% decrease at the end of 8 weeks and that of LDL-cholesterol were 30%. 3) Triglyceride decreased 16% at the end of 8 weeks and increment of HDL-cholesterol was 8% at the end of 8 weeks. 4) No serious side reactions were observed except one patient, who showed generalized skin rash which last 3 days and did not prevent further medication. In conclusion, pravastatin is a safe and useful hypolipidemic agent for the patient with primary hyperlipidemia.

Keyword

Pravastatin; HMG CoA reductase inhibitor; Hyperlipidemia

MeSH Terms

Cholesterol
Cholesterol, LDL
Coenzyme A
Exanthema
Humans
Hyperlipidemias*
Oxidoreductases
Pravastatin*
Triglycerides
Cholesterol
Cholesterol, LDL
Coenzyme A
Oxidoreductases
Pravastatin